Answers are grounded in this paper and cite their sources.
A case report reveals limited benefits from targeted therapies in NSCLC with dual mutations, indicating treatment challenges.
The co-occurrence of actionable driver alterations in non–small cell lung cancer (NSCLC) is rare. Concomitant MET exon 14 skipping ( MET ex14) and KRAS G12C mutations have been only sporadically reported, and the clinical course of the affected patients remains poorly understood. Here, we describe a rare case of advanced invasive mucinous adenocarcinoma harboring both MET ex14 and KRAS G12C mutations. A 69-year-old man was diagnosed with invasive mucinous adenocarcinoma after presenting with multifocal consolidation (cT2bN0M1a, stage IVA). Next-generation sequencing revealed concurrent MET ex14 and KRAS G12C mutations, and the programmed death ligand 1 tumor proportion score was 1%. First-line treatment with tepotinib (500 mg once daily) resulted in stable disease but no objective tumor shrinkage. Disease control was maintained for approximately 8 months before the occurrence of radiographic progression. Second-line therapy with sotorasib (960 mg once daily; later reduced to 480 mg due to edema) produced rapid radiographic progression within 1 month. To our knowledge, this is the first detailed description of the clinical course of a patient with NSCLC harboring concomitant MET ex14 and KRAS G12C mutations, who experienced limited benefit from MET inhibition and demonstrated no clinical response to KRAS inhibition. This case highlights that the coexistence of multiple actionable oncogenic drivers does not necessarily confer additive or parallel therapeutic benefit and provides clinically relevant insights for improving treatment decision-making in cases with tumors with multiple concurrent driver alterations.
No takes yet. Share an insight, caveat, or question.
Hasegawa et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: